Tweeting from the DC Circuit

twitter

A week from today, if the government is still running, we will be squaring off with the FDA on whether cultured stem cells produced by a physician in his or her office for one unique patient are a drug or the practice of medicine. If you want a detailed account of this effort, I‘ve actually written a short book on the topic. In summary, while the agency has taken no issues with our same day procedures, they have objected to the advanced Regenexx-C procedure, claiming that if we culture your cells over several weeks to get more, then we create a prescription drug out of you.  We respectfully think they’re nuts, so we challenged the policy. This has led us to the DC Circuit, where on 10/21 at 9-9:30 am EST I will tweet the blow by blow. It should be an interesting event. My Twitter handle is @CCentenoMD.

Find a Regenexx Location Near You
85 clinic locations offering non-surgical Regenexx solutions for musculoskeletal pain.
85 clinic locations offering non-surgical Regenexx solutions for musculoskeletal pain.
Find a Location
Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

Regenexx Updates in Your Inbox
Join our free newsletter.
Join the Regenexx Newsletter
Subscribe to Blog
TO TOP